Initial Statement of Beneficial Ownership (3)
April 06 2017 - 10:16AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Ryll Thomas
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/29/2017
|
3. Issuer Name
and
Ticker or Trading Symbol
IMMUNOGEN INC [IMGN]
|
(Last)
(First)
(Middle)
C/O IMMUNOGEN, INC., 830 WINTER STREET
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
VP, Technical Operations /
|
(Street)
WALTHAM, MA 02451
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Common Stock
|
106600
(5)
|
D
|
|
Common Stock
|
1500
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (right to buy)
|
8/17/2016
(1)
|
8/17/2025
|
Common Stock
|
60000
|
$14.56
|
D
|
|
Stock Option (right to buy)
|
6/1/2017
(2)
|
6/1/2026
|
Common Stock
|
4000
|
$5.75
|
D
|
|
Stock Option (right to buy)
|
7/18/2017
(3)
|
7/18/2026
|
Common Stock
|
40000
|
$3.05
|
D
|
|
Stock Option (right to buy)
|
9/30/2017
(4)
|
9/30/2026
|
Common Stock
|
38000
|
$2.68
|
D
|
|
Explanation of Responses:
|
(1)
|
15,000 shares exercisable as of filing date, 15,000 shares exercisable commencing on August 17, 2017, 15,000 shares exercisable commencing on August 17, 2018 and 15,000 shares exercisable commencing on August 17, 2019.
|
(2)
|
Exercisable as to 1,334 shares commencing on June 1, 2017, 1,333 shares exercisable commencing on June 1, 2018, and 1,334 shares exercisable commencing on June 1, 2019.
|
(3)
|
Exercisable as to 13,334 shares commencing on July 18, 2017, 13,333 shares commencing on July 18, 2018, and 13,333 shares commencing on July 18, 2019.
|
(4)
|
Exercisable as to 12,667 shares commencing on September 30, 2017, 12,667 shares commencing on September 30, 2018, and 12,666 shares commencing on September 30, 2019.
|
(5)
|
These shares are restricted stock which vest annually in three equal installments commencing on February 21, 2018.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Ryll Thomas
C/O IMMUNOGEN, INC.
830 WINTER STREET
WALTHAM, MA 02451
|
|
|
VP, Technical Operations
|
|
Signatures
|
/s/ Craig Barrows, attorney in fact
|
|
4/6/2017
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024